Per-protocol and as-treated populations
EVENT, RECURRENCE, SILS
In the per-protocol analysis, the 3-year disease-free survival rates were 89.1% (9 of 84) patients who died or had a recurrence calculated by time to event in the SILS + 1 group and 86.8% (12 of 92) in the CLS group, with an absolute difference of 2.3% (1-sided 97.5% CI, − 7.3–7.2%). In the as-treated analysis, the 3-year disease-free survival rates were 89.1% (9 of 84) in the SILS + 1 group and 85.8% (14 of 100) in the CLS group, with an absolute difference of 3.3% (1-sided 97.5% CI, − 6.3–8.2%).